Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GliaSite and Temozolomide for Newly Diagnosed GBM
NCT00376103Phase 2Terminated
- Sponsor
- Methodist Healthcare System of San Antonio
- Start
- Aug 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioblastoma multiforme (GBM), sponsored by Methodist Healthcare System of San Antonio. Primary endpoint: Treatment-related toxicity at 1 year. Started Aug 2006; status: terminated.
02
Drugs
temozolomide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00376103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376103.